title: Caution advised in interpretation of US FDA risk classification for dermatological medications during pregnancy.
abstract: Prescription and non-prescription medications are frequently used by women of childbearing age. As many as 40 to 80 percent of women receive at least one prescription drug during pregnancy. It is essential to understand the potential teratogenicity of medications and offer pregnant women appropriate counseling. Available classification references include the Swedish Catalogue of Approved Drugs, the US Food and Drug Administration, the Australian system, and the Evidence-Based Medicine system.
authors.affiliation: University of California, San Francisco, Department of Dermatology, San Francisco, California, USA.
authors.forename: Jillian W
authors.initials: JW
authors.lastname: Wong
authors.forename: Misha M
authors.initials: MM
authors.lastname: Heller
authors.forename: Jenny E
authors.initials: JE
authors.lastname: Murase
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000517:prevention & control; D003879:Dermatologic Agents / Q000145:classification* / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D003879:Dermatologic Agents